Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Flucelvax Quadrivalent in Children and Adolescents
NCT03165617Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- May 2017
- Primary completion
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of influenza vaccine (cell-based) in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoint: First Occurrence of Either RT-PCR- or Culture-confirmed Influenza Due to Any Influenza Type A or B Strain. Started May 2017; status: completed.
02
Drugs
influenza vaccine (cell-based)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03165617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165617.